p.77 抽出テキスト

317. van Driel VJ, Neven KG, van Wessel H, et al. Pulmonary vein stenosis after catheter ablation: electroporation versus radiofrequency. Circ Arrhythm Electrophysiol 2014; 7: 734-738. PMID: 24958397 318. Kuroki K, Whang W, Eggert C, et al. Ostial dimensional changes after pulmonary vein isolation: pulsed field ablation vs radiofrequency ablation. Heart Rhythm 2020; 17: 1528- 1535. PMID: 32380290 319. Gunawardene MA, Schaeffer BN, Jularic M, et al. Coronary spasm during pulsed field ablation of the mitral isthmus line. JACC Clin Electrophysiol 2021; 7: 1618-1620. PMID: 34600850 320. Reddy VY, Petru J, Funasako M, et al. Coronary arterial spasm during pulsed field ablation to treat atrial fibrillation. Circulation 2022; 146: 1808-1819. PMID: 36134574 321. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357: 2657-2665. PMID: 18160685 322. Kuck KH, Schaumann A, Eckardt L, et al. VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010; 375: 31-40. PMID: 20109864 323. Kuck KH, Tilz RR, Deneke T, et al. SMS Investigators. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 2017; 10: e 004422. PMID: 28292751 324. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016; 375: 111-121. PMID: 27149033 325. Arenal Á, Ávila P, Jiménez-Candil J, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. J Am Coll Cardiol 2022; 79: 1441-1453. PMID: 35422240 326. Tung R, Xue Y, Chen M, et al. PAUSE-SCD Investigators. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. Circulation 2022; 145: 1839-1849. PMID: 35507499 327. Della Bella P, Baratto F, Vergara P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results from the multicenter randomized PARTITA trial. Circulation 2022; 145: 1829- 1838. PMID: 35369700 328. Willems S, Tilz RR, Steven D, et al. BERLIN VT Investigators. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial. Circulation 2020; 141: 1057-1067. PMID: 32000514 329. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol 2015; 1: 116- 123. PMID: 29759353 330. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol 2014; 7: 237- 243. PMID: 24523413 331. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011; 123: 1270-1279. PMID: 21403098 332. Talib AK, Takagi M, Shimane A, et al. Efficacy of endocardial ablation of drug-resistant ventricular fibrillation in Brugada syndrome: long-term outcome. Circ Arrhythm Electrophysiol 2018; 11: e005631. PMID: 30354308 333. Nademanee K, Haissaguerre M, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with early repolarization syndrome. Circulation 2019; 140: 1477- 1490. PMID: 31542949 334. Nademanee K, Chung FP, Sacher F, et al. Long-term outcomes of Brugada substrate ablation: a report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry). Circulation 2023; 147: 1568-1578. PMID: 36960730 335. Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2012; 60: 132-141. PMID: 22766340 336. Jaïs P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation 2012; 125: 2184-2196. PMID: 22492578 337. Anter E, Kleber AG, Rottmann M, et al. Infarct-related ventricular tachycardia: redefining the electrophysiological substrate of the isthmus during sinus rhythm. JACC Clin Electrophysiol 2018; 4: 1033-1048. PMID: 30139485 338. Aziz Z, Shatz D, Raiman M, et al. Targeted ablation of ventricular tachycardia guided by wavefront discontinuities during sinus rhythm: a new functional substrate mapping strategy. Circulation 2019; 140: 1383-1397. PMID: 31533463 339. Hattori M, Komatsu Y, Naeemah QJ, et al. Rotational activation pattern during functional substrate mapping: novel target for catheter ablation of scar-related ventricular tachycardia. Circ Arrhythm Electrophysiol 2022; 15: e010308. PMID: 34937390 340. Jackson N, Gizurarson S, Viswanathan K, et al. Decrement evoked potential mapping: basis of a mechanistic strategy for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol 2015; 8: 1433- 1442. PMID: 26480929 341. de Riva M, Naruse Y, Ebert M, et al. Targeting the hidden substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin Electrophysiol 2018; 4: 316-327. PMID: 30089556 342. Srinivasan NT, Garcia J, Schilling RJ, et al. Multicenter study of dynamic high-density functional substrate mapping improves identification of substrate targets for ischemic ventricular tachycardia ablation. JACC Clin Electrophysiol 2020; 6: 1783- 1793. PMID: 33357574 343. Tung R, Raiman M, Liao H, et al. Simultaneous endocardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll Cardiol 2020; 75: 884-897. PMID: 32130924 344. Valderrábano M, Fuentes Rojas SC, Lador A, et al. Substrate ablation by multivein, multiballoon coronary venous ethanol for refractory ventricular tachycardia in structural heart disease. Circulation 2022; 146: 1644-1656. PMID: 36321460 345. Cuculich PS, Schill MR, Kashani R, et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med 2017; 377: 2325-2336. PMID: 29236642 346. Robinson CG, Samson PP, Moore KMS, et al. Phase I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia. Circulation 2019; 139: 313-321. PMID: 30586734 347. Haskova J, Jedlickova K, Cvek J, et al. Oesophagopericardial fistula as a late complication of stereotactic radiotherapy for recurrent ventricular tachycardia. Europace 2022; 24: 969. PMID: 35138366 348. Nguyen DT, Tzou WS, Sandhu A, et al. Prospective multicenter experience with cooled radiofrequency ablation using high impedance irrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin Electrophysiol 2018; 4: 1176- 1185. PMID: 30236391 349. Garg L, Daubert T, Lin A, et al. Utility of prolonged duration endocardial ablation for ventricular arrhythmias originating from the left ventricular summit. JACC Clin Electrophysiol 2022; 8: 465-476. PMID: 35450601 350. Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy--pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J 2015; 79: 432-438. PMID: 25501800 351. Okumura K, Tomita H, Nakai M, et al. J-RISK AF Research Group. Risk factors associated with ischemic stroke in Japanese patients with nonvalvular atrial fibrillation. JAMA Netw Open 2020; 3: e202881. PMID: 32293685 352. Okumura K, Tomita H, Nakai M, et al. J-RISK AF Research Group. A novel risk stratification system for ischemic stroke in Japanese patients with non-valvular atrial fibrillation. Circ J 2021; 85: 1254- 1262. PMID: 33762526 353. Yamauchi T, Okumura Y, Nagashima K, et al. External validation of the HELT-E2S2 score in Japanese patients with nonvalvular atrial fibrillation ― a pooled analysis of the RAFFINE and SAKURA registries. Circ J 2023; 87: 1777-1787. PMID: 37558457 354. Kodani E, Tomita H, Nakai M, et al. J-RISK AF Research Group. Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF. Eur Heart J Open 2022; 2: oeac081. PMID: 36583077 355. Kodani E, Atarashi H, Inoue H, et al. J‐RHYTHM Registry Investigators. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM registry. J Am Heart Assoc 2016; 5: e004075. PMID: 27620886